[{"id":"c41ce400-a3f3-41d0-9d78-03836538a6de","acronym":"QUILT-2.025","url":"https://clinicaltrials.gov/study/NCT03552718","created_at":"2021-01-18T17:29:26.684Z","updated_at":"2024-07-02T16:35:44.727Z","phase":"Phase 1","brief_title":"QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.","source_id_and_acronym":"NCT03552718 - QUILT-2.025","lead_sponsor":"NantBioScience, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HR positive + HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HR positive + HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YE-NEO 001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 08/10/2018","start_date":" 08/10/2018","primary_txt":" Primary completion: 07/15/2025","primary_completion_date":" 07/15/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-06-26"},{"id":"ce6668ef-0e99-4199-856e-07b1bfdf0be2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05167643","created_at":"2021-12-22T19:15:20.133Z","updated_at":"2024-07-02T16:36:13.476Z","phase":"","brief_title":"H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study","source_id_and_acronym":"NCT05167643","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • PGR positive • HR positive + HER-2 positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • PGR positive • HR positive + HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • TheraCIM (nimotuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/23/2022","start_date":" 01/23/2022","primary_txt":" Primary completion: 10/23/2022","primary_completion_date":" 10/23/2022","study_txt":" Completion: 08/23/2024","study_completion_date":" 08/23/2024","last_update_posted":"2022-04-07"},{"id":"cef0285a-f0d6-427d-8986-f0cac42ed75b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03846583","created_at":"2021-01-18T18:59:22.199Z","updated_at":"2024-07-02T16:36:39.680Z","phase":"Phase 1","brief_title":"Tucatinib + Abemaciclib + Herceptin for HER2+ MBC","source_id_and_acronym":"NCT03846583","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 overexpression • HER-2 amplification • HR positive + HER-2 positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 overexpression • HER-2 amplification • HR positive + HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Verzenio (abemaciclib) • Tukysa (tucatinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/28/2020","start_date":" 06/28/2020","primary_txt":" Primary completion: 09/22/2020","primary_completion_date":" 09/22/2020","study_txt":" Completion: 09/22/2020","study_completion_date":" 09/22/2020","last_update_posted":"2020-10-23"},{"id":"458312b0-4da6-4ced-b732-7d8b6cfdbf3f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04033172","created_at":"2021-01-18T19:47:16.072Z","updated_at":"2024-07-02T16:36:57.695Z","phase":"Phase 2","brief_title":"Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )","source_id_and_acronym":"NCT04033172","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HR positive + HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HR positive + HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • fulvestrant"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 09/01/2021","study_completion_date":" 09/01/2021","last_update_posted":"2019-07-25"},{"id":"154a668a-dde7-4c7a-9d21-45f830f36aa4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02676531","created_at":"2021-01-18T13:02:57.560Z","updated_at":"2024-07-02T16:37:11.635Z","phase":"","brief_title":"Walking Meditation Exercise in Breast Cancer Patients","source_id_and_acronym":"NCT02676531","lead_sponsor":"Chulalongkorn University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HR positive + HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HR positive + HER-2 positive"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 11/01/2017","primary_completion_date":" 11/01/2017","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2018-04-10"}]